
The study examined outcomes for patients with cardiac amyloidosis undergoing LAAO device implantation using the National Readmissions Database (2016-2019). Among 54,900 procedures, 220 (0.4%) had cardiac amyloidosis. These patients faced higher odds of peri-procedural major adverse events and neurological complications but no difference in other peri-procedural complications or readmissions. Future prospective studies are needed to validate these findings.
Like
Save
Share